Cigna, one of the largest health insurers in the United States, has raised its profit outlook for 2026 after its pharmacy benefits business, Evernorth, delivered stronger-than-expected results. The company reported that Evernorth's sales rose 6% to $61.47 billion, helped by faster adoption of biosimilars and specialty generics.
The profit forecast upgrade comes as Cigna beats earnings expectations for the latest quarter, signaling that its strategic pivot away from government-backed health plans is beginning to pay off. The insurer exited the Medicare Advantage market last year and has said it will stop offering Affordable Care Act plans at the end of 2026. That leaves employer-sponsored coverage and the fast-growing Evernorth unit as the twin engines of its business.
What is Evernorth and why does it matter?
Evernorth is Cigna's pharmacy benefits manager (PBM) and specialty drug arm. PBMs act as middlemen between drug manufacturers, insurers, and pharmacies, negotiating discounts and managing prescription drug plans. In recent years, PBMs have come under political scrutiny for their role in drug pricing, but they remain highly profitable for the insurers that own them.
Evernorth's growth is being driven by two specific areas: biosimilars and specialty generics. Biosimilars are lower-cost alternatives to expensive biologic drugs, which are made from living cells and used to treat conditions like arthritis, cancer, and autoimmune diseases. As patents on blockbuster biologics expire, biosimilars are entering the market at a faster pace, and PBMs like Evernorth are well positioned to benefit by steering patients toward these cheaper options.
Specialty generics are another key growth area. These are generic versions of complex, high-cost drugs that treat chronic or rare conditions. Because they are harder to manufacture than standard generics, they face less competition and can command higher margins. Evernorth's ability to manage and distribute these drugs is giving Cigna a competitive edge.
A deliberate shift away from government plans
Cigna's decision to exit Medicare Advantage and stop offering ACA plans marks a significant strategic shift. Medicare Advantage is a private insurance alternative to traditional Medicare, while ACA plans are sold on the public exchanges created by the Affordable Care Act. Both markets have been volatile, with rising medical costs squeezing insurer profits.
By stepping away from those segments, Cigna is focusing on what it does best: managing pharmacy benefits and serving large employer clients. Employer-sponsored insurance tends to be more stable and predictable than government-backed plans, which are subject to regulatory changes and political risk. The company's emphasis on Evernorth also aligns with broader industry trends, as PBMs become increasingly central to the healthcare supply chain.
This is not the first time a company has reshaped its business to focus on higher-growth areas. For context, other firms have also raised forecasts after strong performance in specific divisions. For instance, InterDigital recently raised its 2026 outlook after beating quarterly estimates, and Galderma lifted its sales forecast after an analyst upgrade. While the industries differ, the pattern of companies doubling down on what works is a familiar one in markets.
What it means for investors
For everyday investors, Cigna's profit forecast raise is a signal that the company's strategy is gaining traction. The 6% sales growth at Evernorth is not explosive, but it is steady and driven by structural trends—namely, the shift toward cheaper biologic alternatives and the rising demand for specialty drugs. These are long-term tailwinds that could support earnings for years.
Investors should also note that Cigna's decision to exit government plans reduces its exposure to regulatory risk. The Medicare Advantage and ACA markets have been subject to policy changes that can hurt insurer margins overnight. By focusing on employer coverage and PBMs, Cigna is betting on more predictable revenue streams.
However, the PBM industry is not without risks. Lawmakers in Washington have proposed reforms that could limit how PBMs operate, potentially squeezing their profits. So far, Cigna and its peers have managed to navigate the political environment, but investors should keep an eye on any legislative developments.
Another factor to watch is how Cigna's competitors respond. Other major insurers like UnitedHealth and CVS Health also own large PBM operations. If they follow a similar strategy of pivoting away from government plans, it could intensify competition in the employer and PBM markets. For now, Cigna appears to have a head start.
The broader market context also matters. The healthcare sector has been relatively resilient in 2025, even as other parts of the economy face headwinds from higher interest rates and inflation. Cigna's ability to raise its profit forecast suggests that demand for its services remains strong, which is a positive sign for the sector as a whole.
In summary, Cigna's profit forecast raise is a direct result of Evernorth's strong performance, driven by biosimilars and specialty generics. The company's strategic shift away from government plans is reducing risk and focusing on higher-growth areas. For investors, this is a story of a company adapting to a changing healthcare landscape—and so far, the adaptation is working.
